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Surgical Palliation for Unresectable Pancreatic Carcinoma 
Abstract  
Objective: To review the results of surgical palliation for unresectable pancreatic carcinoma, and 
to analyze the morbidity and mortality associated with the surgical procedure. The reasons for 
readmission after discharge from the hospital were also analyzed. 
Methods: A retrospective study from 1995 to 2001 was done on 30 patients with pancreatic 
cancer operated with palliative intent, or those explored with curative intent but histopathology 
revealed positive resection margins or lymph node metastasis.  
Results: Twenty-five (83.25%) patients were above 50 years of age. There were 16 (53.28%) 
male, and 14 (46.62%) females, 8 (26.64%) had diabetes mellitus, 2 (6.66%) chronic pancreatitis 
and 4 (13.32%) had smoking as risk factors. Twenty-three (76.59%) patients presented with 
jaundice, 18 (59.94%) with weight loss, 17 (56.61%) with epigastric pain, 15 (49.95%) with 
anorexia and 14 (46.62%) with vomiting. Whipple's procedure was performed in 9 (29.97%) 
patients, triple bypass in 13 (43.29%), choledochojejunostomy and gastrojejunostomy in 3 
(9.99%) and gastrojejunostomy alone in 5 (16.65%) patients. Seven (23.31%) patients had 
preoperative ultrasonography, while CT Scan was done in 24 (79.92%) and ERCP in 8 (26.64%) 
patients. Histopathology showed positive resection margins in 9 (29.97%) patients and lymph 
node metastasis in 5 (16.65%) patients. Seventeen (56.61%) patients received less than 2 units of 
pack cells transfusion. Most of the patients remained admitted in the hospital between 20 to 30 
days. Post-operatively, delayed gastric emptying was detected in 6 (19.98%) patients, cholangitis 
in 2 (6.66%), wound infection in 3 (9.99%), anastomotic leak in 2 (6.66%) and line sepsis in 2 
(6.66%) patients. Three (9.99%) patients expired in hospital post operatively. The reasons for re-
admission after discharge included abdominal pain in 9 (29.97%) patients, anemia in 3 (9.99%), 
intestinal obstruction in 3 (9.99%) and urinary tract infection in 2 (6.66%) patients. Follow up 
record was available for 22 (73.26%) patients. Six (19.98%) patients survived for 5 to 6 months 
and 9 (29.97%) had a survival between 7 to10 months. 
Conclusion: A single surgical procedure can palliate all three symptoms associated with 
unresectable pancreatic carcinoma, and can be carried out with reasonable safety in selected 
patients. The commonest indication for re-admission is severe abdominal pain associated with 
advanced malignancy, hence chemical splanchiectomy may also be considered at the time of 
surgical exploration (JPMA 54:601;2004). 
Introduction  
Monteire first described carcinoma of the pancreas in 1836. It is the fifth leading cause of cancer 
related deaths in United States.1 Significant progress has been made during the last decade in 
two aspects. First, the operative results for pancreaticoduodenectomy performed for curative 
intent.2 Second, survival in operated patients for palliation.3,4 It is a disease with poor 
prognosis. Less than 20% of affected patients had a survival of one year, and five-year survival is 
less than 3%.5-7 Only 15% of the patients have resectable tumor at the time of presentation.8 
With this unfortunate outcome palliation of symptoms to improve the quality of life is of primary 
importance in majority of the patients. Palliation of pancreatic carcinoma is mainly directed at 
three symptoms, obstructive jaundice, duodenal obstruction and pain.9 Painless jaundice has 
been ascribed as pathogonomic in victims of pancreatic cancer, but 30% to 40% of these patients 
do in fact have pain. 10  
The purpose of this study is to review the results of surgical palliation in patients with 
unresectable pancreatic carcinoma, to see the complications and to understand the reasons of 
readmission after discharge from the hospital. 
Patients and Methods  
This is a retrospective review at The Aga Khan University Hospital, over a seven years period, 
from 1995 to 2001. All the patients diagnosed to have carcinoma of the pancreas and operated 
with palliative intent or the patients operated with curative intent, but histopathology showed 
positive resection margins or lymph node metastasis were included in the study. Multiple 
parameters were analyzed, including presence of risk factors, the presenting symptoms and their 
duration and co-morbid conditions. The diagnostic modalities used were computerized 
tomographic scan in majority of the patients. However ultrasonography was also employed in 
some patients. 
Surgical procedures performed, were triple bypass in most of the patients. 
Pancreaticoduodenectomy was performed in 9 patients. Choledochojejunostomy and 
gastrojejunostomy and only gastrojejunostomy were also performed. Complications after surgery 
and in-hospital mortality were analyzed. 
The reasons of readmission after the discharge from the hospital, and follow up of these patients 
were also assessed. 
Results  
There were 30 patients included in the study. The mean age was 60 + 10 years. There were 16 
(53.28%) male and 14 (46.62%) females. Diabetes mellitus was a risk factor in 8 (26.64%) 
patients, smoking in 4 (13.32%) and 2 (6.66%) had chronic pancreatitis. Jaundice, weight loss 
and abdominal pain were common symptoms at the time of presentation. The symptoms and the 
duration of these symptoms are shown in Table. 
The mean hemoglobin was less than 10 gm/dl in 7 (23.31%) patients while 18 (59.94%) had a 
hemoglobin level of more than 10 gm/dl at the time of admission. The serum bilirubin level was 
more than 5mg/dl in 21 (69.93%) patients and less than 5 mg/dl in 9 (29.97%). Hypertension was 
present in 9 (29.97%) individuals and 7 (23.31%) had ischemic heart disease as co- morbid 
conditions.  
Ultrasonography was used as a diagnostic modality in 7 (23.31%) cases and computerized 
tomographic scan was  
Table. Clinical presentation and duration of symptoms.  
 
Symptoms  No. of  Mean Duration  Range  
  patients  of symptoms  (days)  
   (days)   
 
Jaundice 23 (76.59%) 48  10-120 
Weight loss 18 (59.94%) 60  20-120 
Abdominal Pain 17 (56.61%) 38  10-90 
Anorexia 15 (49.95%) 36  14-45 
Vomiting 14 (46.62%) 40  2-90 
Fever 5 (16.65%) 10  2-20 
Abdominal Mass 4 (13.32%) 16  7-30 
The mean hemoglobin was less than 10 gm/dl in 7 (23.31%) patients while 18 (59.94%) had a 
hemoglobin level of more than 10 gm/dl at the time of admission. The serum bilirubin level was 
more than 5mg/dl in 21 (69.93%) patients and less than 5 mg/dl in 9 (29.97%). Hypertension was 
present in 9 (29.97%) individuals and 7 (23.31%) had ischemic heart disease as co- morbid 
conditions.  
Ultrasonography was used as a diagnostic modality in 7 (23.31%) cases and computerized 
tomographic scan was done in 24 (79.92%). Unresectability of the tumor on CT scan could be 
detected in 11 (36.63%) subjects. ERCP was performed in 8 (26.64%), but it failed in 4 (13.32%) 
patients. Stenting could be done in 4 (13.32%) patients, but 2 (6.66%) subsequently developed 
cholangitis and the stent has to be removed. 
Pancreaticoduodenectomy was performed in 9 (29.97%) patients, triple bypass in 13 (43.29%), 
choledochojejunostomy and gastrojejunostomy in 3 (9.99%) and gastrojejunostomy alone in 5 
(16.65%) patients. Unresectability was detected peroperatively in 21(69.93%) patients. Adjacent 
organ invasion and liver metastasis were the common findings in these cases. 
Pancreaticoduodenectomy was performed in 9 (29.97%) patients with curative intent, but 
histopathology showed positive resection margins in these cases and 5 (16.65%) patients had 
lymph node metastasis. Less than 2 packed cells transfusion were required in 17 (56.61%) 
patients while 4 (13.32%) required more than 4 packed cells transfusion. Fourteen (46.62%) 
patients required intensive unit care for 1 to 5 days and 6 (19.98%) required 6 to 10 days of ICU 
admission. The mean hospital stay was 20 + 5 days (range 10 to 32 days). 
Delayed gastric emptying was detected in 6 (19.98%) patients who were subjected to 
pancreaticoduodenectomy. Cholangitis occurred in 2 (6.66%) patients and treated with 
antibiotics. Wound infection was encountered in 3 (9.99%) cases. Anastomotic leakage from 
choledochojejunal anastomosis occurred in 2 (6.66%) patients and both were treated 
conservatively. One (3.33%) patient had myocardial infarction and another (3.33%) developed 
deep vein thrombosis in the left leg. Three (9.99%) patients died in the hospital, postoperatively, 
2 (6.66%) developed pneumonia, adult respiratory distress syndrome and multiorgan failure and 
one (3.33%) had myocardial infarction. 
The commonest reason of readmission after discharge from the hospital was severe abdominal 
pain, which occurred in 9 (29.97%) patients. Three (9.99%) were readmitted with intestinal 
obstruction, 2 (6.66%) with anemia, 2 (6.66%) with urinary tract infection and 3 (9.99%) were 
admitted for terminal care. The follow up record was available for 22 (73.26%) patients. Six 
(19.98%) had a survival of 1 to 4 months; another 6 (19.98%) had a survival of 5 to 6 months, 
while 9 (29.97%) patients had a survival of 7 to 10 months. One (3.33%) case having a survival 
of 10 months is still alive at the time of completion of this study. 
Discussion  
Pancreaticoduodenectomy has been advocated as the optimal treatment for pancreatic cancer.11 
Majority of the patients have advanced disease, and only 15% have resectable disease at the time 
of their presentation.8 
Identification of a high risk group of patients is difficult.12 The different risk factors associated 
with carcinoma of pancreas are smoking, increased intake of fat and meat, prior peptic ulcer 
surgery, diabetes mellitus and chronic pancreatitis.5 There is a weak association between coffee 
consumption and carcinoma of pancreas.13 In our study, 8 (26.64%) patients had diabetes 
mellitus and 4 (13.32%) had smoking as risk factors. A well defined high risk group of patients 
for prospective screening has not been identified. 
Majority of the cancers of the pancreas arise in the head of the gland, therefore obstructive 
jaundice is the common presenting symptom, reported in about 70% of the cases.14 In our study 
23 (76.59%) patients had obstructive jaundice. Studies have shown that 30% to 50% of patients 
with pancreatic cancer present with vomiting.14 In our study 14 (46.63%) patients had vomiting 
at the time of presentation. Pain is the incapacitating symptom of pancreatic cancer. Literature 
shows that 30% to 40% of patients have pain at presentation. In our study, 17 (56.61%) patients 
came with pain as the principal symptom. 
The results for palliation of obstructive jaundice, either by surgical bypass or by endoscopic 
techniques are good with a success rate of over 90%.8 Recurrent jaundice has been noticed in 
17% to 38% of stented patients and rarely seen in operated patients.15 The incidence of late 
duodenal obstruction in endoscopic group is 9% to 14%.16 ERCP was attempted in 8 (26.64%) 
patients in our study, but it was successful in 4 (13.32%) only and 2 (6.66%) of these patients 
required removal of their stents due to cholangitis. 
The role of pancreaticoduodenectomy for palliation of pancreatic cancer is limited. 
Pancreaticoduodenectomy was found to be curative in 59% of patients in one study.17 The mean 
survival in these patients was 10 months.18 In our study 9 (29.97%) patients had positive 
resection margins after pancreaticoduodenectomy. Their mean survival was 9 months. 
The incidence of postoperative complications ranges from 15% to 30% in the literature. Ten 
(33.30%) patients developed complications after surgery in our study. Pain is the most disturbing 
symptom of pancreatic cancer. Intra-operative chemical splanchniectomy has been described as 
an effective modality of pain control.10 Pain relief after this procedure has been achieved in 60% 
to 88% of the patients.19 Chemical splanchniectomy was not done in our study, and 9 (29.97%) 
patients were readmitted with severe abdominal pain. 
In conclusion, surgical management provides a single procedure that can treat all three symptoms 
associated with pancreatic carcinoma. Therefore, surgical palliation is a good option in selected 
patients with unresectable pancreatic cancer. As the commonest indication for re-admission is 
severe abdominal pain associated with advanced malignancy, chemical splanchiectomy may also 
be considered at the time of surgical exploration. 
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